Medicenna Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year	2022	2021	2020	2019	2018
Cash & Equivalents	33.6	20.54	30.38	22.7	2.37
Short-Term Investments	0	0	10.01	15	0
Cash & Cash Equivalents	33.6	20.54	40.39	37.7	2.37
Cash Growth	63.60%	-49.15%	7.12%	1490.10%	-
Receivables	0.86	1.31	0.41	0.06	2.48
Other Current Assets	1.93	1.55	1.35	0.09	0.26
Total Current Assets	36.39	23.39	42.15	37.85	5.11
Property, Plant & Equipment	0	0	0.03	0.07	0
Goodwill and Intangibles	0.06	0.07	0.07	0.08	0.08
Total Long-Term Assets	0.06	0.07	0.1	0.14	0.08
Total Assets	36.45	23.46	42.25	38	5.19
Accounts Payable	3.8	2.62	4.07	1.78	2.4
Current Debt	0	0	0.03	0.04	0
Total Current Liabilities	3.8	2.62	4.11	1.82	2.4
Long-Term Debt	0	0	0	0.03	0
Other Long-Term Liabilities	3.16	0	0	0	0.17
Total Long-Term Liabilities	3.16	0	0	0.03	0.17
Total Liabilities	6.96	2.62	4.11	1.85	2.57
Total Debt	0	0	0.03	0.07	0
Debt Growth	-	-	-49.25%	-	-
Retained Earnings	-80.98	-70.93	-48.36	-31.07	-22.79
Comprehensive Income	0.06	0.17	0.23	0.25	0.16
Shareholders' Equity	29.49	20.84	38.15	36.15	2.62
Net Cash / Debt	33.6	20.54	40.35	37.63	2.37
Net Cash / Debt Growth	63.60%	-49.11%	7.22%	1487.28%	-
Net Cash Per Share	0.52	0.38	0.81	1.18	0.09
Working Capital	32.59	20.77	38.04	36.04	2.71
Book Value Per Share	0.46	0.38	0.77	1.13	0.10

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).